In a quiet corner of a medical conference, a West Virginia researcher offered a small, cautious light: among young children with eosinophilic esophagitis, those given dupilumab early seemed less likely to later develop asthma. The observation draws on a vast body of health records, and it touches an old human puzzle, the way allergic conditions gather and travel together through childhood. Yet the finding remains a question rather than an answer, and its authors say so plainly, waiting for prospective studies and eventually a randomized trial to show whether calming inflammation early can trul
Early Dupilumab for Eosinophilic Esophagitis May Be Linked to Lower Asthma Risk in Young Children
In a quiet corner of a medical conference, a West Virginia researcher offered a small, cautious light: among young children with eosinophilic esophagitis, those given dupilumab early seemed less likely to later develop asthma. The observation draws on a vast body of health records, and it touches an old human puzzle, the way allergic conditions gather and travel together through childhood. Yet the finding remains a question rather than an answer, and its authors say so plainly, waiting for prospective studies and eventually a randomized trial to show whether calming inflammation early can truly bend the course of a child's allergic life.
At the annual meeting of the American College of Allergy, Asthma & Immunology, Kayla Steinberger of West Virginia University presented a finding that offers hope without yet offering proof. Young children with eosinophilic esophagitis who were treated early with dupilumab appeared less likely to develop asthma later on.
The data came from a large commercial insurance and health records network. Among children who began dupilumab before age 6, 8.1% developed asthma over roughly 3.5 years, compared with 16.0% of children with esophagitis who never received the drug. The comparison group was matched on age, sex, race, and atopic dermatitis, and the difference was statistically strong. But the design is observational, and Steinberger was clear that unmeasured factors such as disease severity, adherence, and treatment indication could still shape the result.
The work sits within the atopic march, the familiar pattern in which allergic conditions appear in sequence or cluster in the same child. Steinberger believes early blockade of the IL-4 and IL-13 pathways may influence that progression, since such therapies act across several immune cells and tissues at once. She noted that IL-5 inhibitors may not reach far enough upstream to have the same effect.
Her proposed path is deliberate: validate the pattern in independent populations, then run prospective studies with standardized asthma criteria and biomarker tracking, and finally test the question in a randomized trial. For now, the result is a signal to watch, not a recommendation to change care.
In a poster session at the annual meeting of the American College of Allergy, Asthma & Immunology, Kayla J. Steinberger, MD, PhD, of West Virginia University in Morgantown, presented a finding that points in a hopeful direction but is not yet proof of anything: young children with eosinophilic esophagitis who were treated with dupilumab (Dupixent) were less likely to develop asthma later on.
The numbers come from a large commercial insurance database. Among children who began the biologic before age 6 and had been off it for at least a year afterward, 8.1% developed asthma over the following 3.5 years. Among children who had eosinophilic esophagitis but never received dupilumab, the figure was 16.0% (P=0.0002).
The background is the atopic march, the tendency of allergic conditions to appear in sequence or cluster in the same child. Children with eosinophilic esophagitis are known to be at higher risk of asthma. Dupilumab blocks signaling of interleukin 4 and interleukin 13, and it is approved for both conditions. It is the only biologic with FDA approval for eosinophilic esophagitis. Its approval for that condition extends down to age 1, while for asthma it is approved only after age 6. Steinberger said the team's results raised the possibility that early biological therapy might modify the progression of the atopic march.
The team drew on the U.S. Collaborative Network of the TriNetX research platform, which holds electronic health records on about 140 million patients and insurance claims on 200 million. The retrospective cohort compared 698 matched children who took dupilumab before age 6, at an average age of 3.2 years at initiation, with 698 children who took the corticosteroid budesonide instead. The period covered was Jan. 1, 2016 to Jan. 1, 2026. Matching by propensity score accounted for age, sex, race, and atopic dermatitis diagnosis. Children with asthma at baseline before age 7 were excluded. About 74% of the children were male, 63% were white, and 46% had atopic dermatitis.
Steinberger was direct about the limits. She called the work hypothesis-generating, since a retrospective observational design cannot establish causality. Propensity matching addresses measured confounders, she said, but differences in disease severity, treatment indication, medication adherence, and healthcare utilization may still shape the association.
Her proposed path forward has stages. First would be validation in independent longitudinal pediatric populations with more detailed clinical characterization and longer follow-up. Ideally a prospective study would then compare early dupilumab with an appropriate comparator group, using standardized asthma diagnostic criteria and tracking type 2 inflammatory biomarkers and pulmonary outcomes over time. A randomized controlled trial would give the strongest answer on whether targeting IL-4/IL-13 early can change the natural history of type 2 inflammatory disease rather than treating each manifestation as it arises.
Steinberger told MedPage Today that atopic disease in young children is driven by T2 inflammation, and that biologics acting on pathways across multiple immune cells and the epithelium have the best potential to treat several atopic conditions in different organ systems, possibly lowering incidence by keeping the inflammation at bay.
She suggested other biologics might show similar effects, but the pathway targeted likely matters. IL-5 inhibitors such as mepolizumab (Nucala), reslizumab (Cinqair), and benralizumab (Fasenra) are generally not considered strong enough to modify the atopic march, she said, and she asked whether IL-5 signaling sits too far downstream to affect the other pathways in type 2 inflammation. She added that other studies have hinted early treatment might help prevent conditions like eczema, though some recent work challenges the linear model of progression and suggests certain groups are at highest risk and worth targeting.
For now the result is a signal, not a recommendation. What to watch is whether prospective data, and eventually a randomized trial, can confirm it.
Citazioni salienti
The findings raised the possibility that early biological therapy may modify the progression of the atopic march.— Kayla J. Steinberger, MD, PhD, West Virginia University
Propensity matching addresses measured confounders, but residual confounding may still influence the observed association; a randomized trial would provide the strongest evidence.— Kayla J. Steinberger (paraphrased)
Vuoi la storia completa?
Leggi l'originale su MedPage Today ↗